Badhma Valaiyapathi1, David A Calhoun2. 1. Department of Vascular Biology and Hypertension Program, University of Alabama at Birmingham, Birmingham, AL, USA. 2. Department of Vascular Biology and Hypertension Program, University of Alabama at Birmingham, Birmingham, AL, USA. dacalhoun@uabmc.edu.
Abstract
PURPOSE OF REVIEW: This review will summarize recent developments in the research on the mineralocorticoid receptor and its impact on obstructive sleep apnea and metabolic syndrome. RECENT FINDINGS: Aldosterone excess plays an important role in the association between resistant hypertension and obstructive sleep apnea. The prevalence of obesity is increasing rapidly worldwide and is especially common among patients with obstructive sleep apnea, resistant hypertension, and metabolic syndrome, suggesting probable mechanistic links between these three conditions. Mineralocorticoid receptor expression is increased in obese individuals, which may contribute to the common association between obesity and hyperaldosteronism. Mineralocorticoid receptor blockers reduce the severity of obstructive sleep apnea among resistant hypertension patients. A large body of literature demonstrates a strong association between obesity, hyperaldosteronism, resistant hypertension, and sleep apnea, including specific benefit of treatment with mineralocorticoid receptor blockers for these separate disorders.
PURPOSE OF REVIEW: This review will summarize recent developments in the research on the mineralocorticoid receptor and its impact on obstructive sleep apnea and metabolic syndrome. RECENT FINDINGS: Aldosterone excess plays an important role in the association between resistant hypertension and obstructive sleep apnea. The prevalence of obesity is increasing rapidly worldwide and is especially common among patients with obstructive sleep apnea, resistant hypertension, and metabolic syndrome, suggesting probable mechanistic links between these three conditions. Mineralocorticoid receptor expression is increased in obese individuals, which may contribute to the common association between obesity and hyperaldosteronism. Mineralocorticoid receptor blockers reduce the severity of obstructive sleep apnea among resistant hypertensionpatients. A large body of literature demonstrates a strong association between obesity, hyperaldosteronism, resistant hypertension, and sleep apnea, including specific benefit of treatment with mineralocorticoid receptor blockers for these separate disorders.
Authors: Francesco Fallo; Franco Veglio; Chiara Bertello; Nicoletta Sonino; Paolo Della Mea; Mario Ermani; Franco Rabbia; Giovanni Federspil; Paolo Mulatero Journal: J Clin Endocrinol Metab Date: 2005-11-15 Impact factor: 5.958
Authors: A G Logan; S M Perlikowski; A Mente; A Tisler; R Tkacova; M Niroumand; R S Leung; T D Bradley Journal: J Hypertens Date: 2001-12 Impact factor: 4.844
Authors: Murielle Bochud; Jürg Nussberger; Pascal Bovet; Marc R Maillard; Robert C Elston; Fred Paccaud; Conrad Shamlaye; Michel Burnier Journal: Hypertension Date: 2006-06-19 Impact factor: 10.190
Authors: Monique N Pratt-Ubunama; Mari K Nishizaka; Robyn L Boedefeld; Stacey S Cofield; Susan M Harding; David A Calhoun Journal: Chest Date: 2007-02 Impact factor: 9.410
Authors: José Boggia; Yan Li; Lutgarde Thijs; Tine W Hansen; Masahiro Kikuya; Kristina Björklund-Bodegård; Tom Richart; Takayoshi Ohkubo; Tatiana Kuznetsova; Christian Torp-Pedersen; Lars Lind; Hans Ibsen; Yutaka Imai; Jiguang Wang; Edgardo Sandoya; Eoin O'Brien; Jan A Staessen Journal: Lancet Date: 2007-10-06 Impact factor: 79.321
Authors: Ian J Neeland; Bjorn Eliasson; Takatoshi Kasai; Nikolaus Marx; Bernard Zinman; Silvio E Inzucchi; Christoph Wanner; Isabella Zwiener; Brian S Wojeck; Henry K Yaggi; Odd Erik Johansen Journal: Diabetes Care Date: 2020-10-01 Impact factor: 19.112